Lilly’s Zepbound and Foundayo Secure Coverage From All Three Major US PBMs

Why It Matters

Universal PBM coverage for Lilly’s obesity drugs removes a key access barrier, allowing clinicians to prescribe the most suitable therapy without formulary constraints. For patients, the inclusion of an oral GLP‑1 expands treatment options beyond injections, likely increasing adherence and accelerating weight‑loss outcomes. For the broader health‑care market, the development signals a shift toward broader acceptance of oral GLP‑1 agents and intensifies competition in the obesity space. Insurers may leverage the cost‑savings negotiated by CVS Caremark to pressure other manufacturers, potentially compressing pricing across the class and reshaping reimbursement models. The move also underscores the strategic importance of PBM negotiations in drug commercialization. By securing all three major PBMs, Lilly not only safeguards its market share but also creates a template for future launches of high‑value therapies that depend on formulary placement to achieve scale.

Key Takeaways

• Lilly’s Zepbound and oral GLP‑1 Foundayo now covered by Express Scripts, Optum Rx and CVS Caremark
• CVS Caremark formulary reaches ~25‑30 million Americans, unlocking new patient volume
• Foundayo prescribed to ~20,000 patients in first weeks, 80% new‑to‑class users
• Zepbound volume up 80% in 2025; realized price fell 13% in Q1 2026
• Lilly Q1 revenue $19.80 billion, up 55.5% YoY; full‑year guidance raised to $82‑$85 billion

Pulse Analysis

Lilly’s sweep of the three dominant PBMs is more than a distribution win; it is a strategic lever that could redefine the economics of obesity treatment in the United States. By aligning with Express Scripts, Optum Rx and CVS Caremark, Lilly eliminates the last major formulary obstacle that has historically limited GLP‑1 uptake, especially for newer oral agents. The oral format of Foundayo addresses a long‑standing patient‑level friction—needle aversion—potentially expanding the addressable market beyond the traditional GLP‑1 user base.

From a competitive standpoint, the move neutralizes Novo Nordisk’s temporary advantage after CVS dropped Zepbound in 2025. With both companies now on equal footing across the largest PBMs, the battle will shift to pricing, efficacy data, and real‑world adherence. Lilly’s ability to negotiate 10‑15% cost reductions for CVS clients suggests that the company can offer compelling value propositions, which may force Novo to revisit its own pricing structures or accelerate development of oral formulations.

Looking forward, the October 1 co‑preferred status for Zepbound will be a litmus test for how quickly insurers can integrate dual‑brand strategies without cannibalizing each other’s volume. If Lilly can sustain the 80% volume growth while stabilizing prices, the company could solidify a dominant position in a market projected to exceed $30 billion by 2030. The universal PBM coverage thus not only fuels short‑term revenue upside but also sets the stage for long‑term market leadership in obesity therapeutics.